1.Department of Respiration, the First Affiliated Hospital of Gannan Medical University, Jiangxi Province, Ganzhou 341000, China;
2.Department of Pathology, the First Affiliated Hospital of Gannan Medical University, Jiangxi Province, Ganzhou 341000, China;
3.Blood Laboratory, the First Affiliated Hospital of Gannan Medical University, Jiangxi Province, Ganzhou 341000, China
Abstract：Objective To explore the value of detecting vascular endothelial growth factor (VEGF), epidermal growth factor (EGFR) and CD40 in differential diagnosis of benign and malignant pleural effusion. Methods Sixty patients with lung cancer and pleural effusion hospitalized and diagnosed in the First Affiliated Hospital of Gannan Medical University from June 2015 to June 2017 were selected as observation group. 60 tuberculous pleurisy patients with pleural effusion in the same period were selected as control group. The expression levels of VEGF, EGFR and CD40 in pleural effusion samples of all patients were detected and compared between two groups. The diagnostic value of each index for malignant pleural effusion was analyzed by receiver operating characteristic curve (ROC). Results The expression level of VEGF, EGFR and CD40 in pleural effusion of observation group was significantly higher than those of control group, the difference was statistically significant (P ＜ 0.05). ROC curve analysis showed that the area under the curve of VEGF in the diagnosis of malignant pleural effusion was 0.840, with 893.50 pg/mL as the cut-off point, the sensitivity was 70.00%, and the specificity was 91.70%. The area under the curve of EGFR in the diagnosis of malignant pleural effusion was 0.839, and the cut-off point was 29.50 mg/L. The sensitivity was 80.00% and specificity was 88.30%. The area under the curve of CD40 in the diagnosis of malignant pleural effusion was 0.911, and the cut-off point was 41.50 pg/mL. The sensitivity was 85.00% and the specificity was 93.30%. The diagnostic efficiency of CD40 in benign and malignant pleural effusion was better than that of VEGF and EGFR. Conclusion The expression of VEGF, EGFR and CD40 in malignant pleural effusion is significantly increased, the three methods have certain diagnostic value in differentiating benign and malignant pleural effusion. However, the sensitivity and specificity of CD40 in the diagnosis of malignant pleural effusion is higher than that of VEGF and EGFR.
[1] Maebayashi T，Ishibashi N，Aizawa T，et al. Radiation pneumonitis changes over time after stereotactic body radiation therapy for lung tumors：post-treatment cavity （sunny-side-up egg-like） changes [J]. Anticancer Res，2016，36（10）：5563-5570.
[2] 刘洪建，王玉波，解桢，等.VEGF水平与恶性胸腔积液的相关性研究[J].中国生化药物杂志，2015，35（3）：141-143.
[3] 林钟.胸水VEGF、P53联合CEA检测在肺癌诊断中的价值[J].临床医学工程，2018，25（7）：889-890.
[4] 刘冲，李涛，季盼，等.肺腺癌胸水细胞蜡块表皮生长因子受体检测的价值[J].江苏医药，2018，44（8）：895-897， 977.
[5] 卢旭东，周兴菊，陆益民.肺癌患者胸水CD40、MMP-12水平的检测及临床意义[J].临床肺科杂志，2015，20（7）：1174-1176.
[6] 支修益，杨跃，王长利，等.原发性肺癌诊疗规范（2015年版）：外科部分[J].中国医学前沿杂志：电子版，2015，7（2）：28-31.
[7] Hida T，Matsumoto S，Hamasaki M，et al. Deletion status of p16 in effusion smear preparation correlates with that of underlying malignant pleural mesothelioma tissue [J]. Cancer Sci，2015，106（11）：1635-1641.
[8] Wong MCS，Lao XQ，Ho KF，et al. Incidence and mortality of lung cancer：global trends and association with socioeconomic status [J]. Sci Rep，2017，7（1）：14300.
[9] Chen W，Zheng R，Baade PD，et al. Cancer statistics in China，2015 [J]. CA Cancer J Clin，2016，66（2）：115-132.
[10] Karzijn R，Alberts L，Kelder JC，et al. Post-treatment surveillance for stage Ⅰ and Ⅱ non-small cell lung cancer：impact on clinical outcome [J]. Anticancer Res，2016， 36（10）：5413-5418.
[11] 胡婕.MACC1和c-MET检测在肺腺癌并发恶性胸腔积液中的诊断价值[D].合肥：安徽医科大学，2016.
[12] 苗凯玲，李春燕，侯惠如.肺癌恶性胸腔积液置管引流患者生活质量调查及影响因素分析[J].中国医药导报，2018，15（22）：64-68.
[13] 白大鹏，梅早仙.血管内皮生长因子在胸膜疾病中的研究进展[J].继续医学教育，2016，30（9）：92-94.
[14] Bradshaw M，Mansfield A，Peikert T. The role of vascular endothelial growth factor in the pathogenesis，diagnosis and treatment of malignant pleural effusion [J]. Curr Oncol Rep，2013，15（3）：207-216.
[15] Bayram N，Karakan Y，Uyar M，et al. Vascular endothelial growth factor in pleural effusions and correlation with radiologic and biochemical parameters [J]. Niger J Clin Pract，2018，21（1）：59-62.
[16] 田瑞.趋化因子CXCL13、CXCL16联合VEGF在良恶性胸腔积液中的鉴别诊断[D].保定：河北大学，2018.
[17] 叶飒，王飞燕，周宏斌，等.非小细胞肺癌患者血清IL-17、VEGF水平与临床分期和预后的相关性研究[J].浙江医学，2018，40（6）：573-576.
[18] Popper HH. Progression and metastasis of lung cancer [J]. Cancer Metastasis Rev，2016，35（1）：75-91.
[19] 张连美，仲纪祥，孙苏安.EGFR、ALK和Ki-67在非小细胞肺癌中的表达及相关性分析[J].临床肺科杂志，2017， 22（1）：4-7.
[20] Ruibal ?譧，Aguiar P，Del Río MC，et al. Cell membrane CD44v6 levels in squamous cell carcinoma of the lung：association with high cellular proliferation and high concentrations of EGFR and CD44v5 [J]. Int J Mol Sci，2015，16（3）：4372-4378.
[21] 田野，王园，刘思洋，等.肺癌伴恶性胸腔积液中EGFR突变检测及其临床意义[J].中国医科大学学报，2016， 15（2）：150-153.
[22] Hu CY，Zhang XA，Meyer CG，et al. Polymorphism of X-linked CD40 ligand gene associated with pulmonary tuberculosis in the Han Chinese population [J]. Genes Immun，2015，16（6）：399-404.
[23] 梅齐，吴骁伟，李杨，等.肺癌患者胸腔积液中血管内皮生长因子及CD40检测的临床意义[J].肿瘤研究与临床，2016，28（7）：480-483.
[24] 吕彦天，孙晓静，陈成，等.PI3K-AKT信号在CD40分子调节肺癌细胞侵袭能力中的作用[J].中华医学杂志，2013，93（10）：775-779.
2019, Vol. 16 
京公网安备 11010502046598号